OTEZLA(R) (apremilast) phase III data showed significant improvements in patients
Celgene announced data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet's Disease with oral ulcers. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily versus placebo through week 12. February 17, 2018